We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Avenue Therapeutics

News List

Avenue Therapeutics Receives Complete Response Letter from FDA for IV Tramadol americanpharmaceuticalreview
October 16, 2020
Avenue Therapeutics has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company’s New Drug Application (NDA) for IV tramadol.
Avenue Therapeutics receives complete response letter from the FDA for IV Tramadol expresspharma
October 14, 2020
The CRL stated that IV tramadol, intended to treat patients in acute pain who require an opioid, is not safe for the intended patient population.
InvaGen to acquire Avenue Therapeutics for $215m pharmaceutical-technology
November 14, 2018
InvaGen Pharmaceuticals, a unit of India-based Cipla, has signed definitive agreements to buy US-based specialty pharmaceutical firm Avenue Therapeutics for a total consideration of $215m.